Myocardial interaction of apixaban after experimental acute volume overload (original) (raw)
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries
Giovanni Giurdanella
Frontiers in Pharmacology
View PDFchevron_right
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of …
Puneet Mohan, Deepak L . Bhatt
Circulation, 2009
View PDFchevron_right
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome
J. López-sendon
Circulation, 2009
View PDFchevron_right
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
Puneet Mohan
Circulation, 2009
View PDFchevron_right
Perspectives: Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease
Carlos Santos-Gallego
European Heart Journal Supplements, 2014
View PDFchevron_right
Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB
Lori Wetmore
BMC pharmacology & toxicology, 2014
View PDFchevron_right
Factor Xa inhibitors for acute coronary syndromes
Viviana Brito
Reviews, 1996
View PDFchevron_right
P1660Effects of factor Xa inhibitors rivaroxaban and apixaban on platelet function
Giulia Renda
European Heart Journal, 2017
View PDFchevron_right
Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression
Dimcho Bachvarov
Canadian Journal of Physiology and Pharmacology, 2002
View PDFchevron_right
Surgical Acute Volume-Overload Impacts Early on Myocardium - An Experimental Study
Ari Mennander
Acta Cardiologica Sinica, 2017
View PDFchevron_right
Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a
Сергей Владимирович Оковитый
International Journal of Molecular Sciences
View PDFchevron_right
Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves
Teresa Iwaniec
Vascular Pharmacology, 2020
View PDFchevron_right
The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats
Nicholas Cicutti
Cardiovascular Research, 1996
View PDFchevron_right
The new factor Xa inhibitor: Apixaban
Sangeeta Bhanwra
Journal of Pharmacology and Pharmacotherapeutics, 2014
View PDFchevron_right
Celecoxib but not rofecoxib nor naproxen attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone
Raymond Cheung
Clinical and Experimental Pharmacology and Physiology, 2010
View PDFchevron_right
Time Courses of Subcellular Signal Transduction and Cellular Apoptosis in Remote Viable Myocardium of Rat Left Ventricles Following Acute Myocardial Infarction: Role of Pharmacomodulation
Ali Youssef, Sarah Chua, Hon-kan Yip
View PDFchevron_right
Role of oral factor Xa inhibitors after acute coronary syndrome
ABHISHEK SHARMA
Cardiology, 2014
View PDFchevron_right
Effect of captopril on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy
Luis Peres
American Heart Journal, 1992
View PDFchevron_right
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
František Kovář
European Heart Journal, 2011
View PDFchevron_right
Effects of Matrix Metalloproteinase Inhibition on Ventricular Remodeling Due to Volume Overload
John Wright
Circulation, 2002
View PDFchevron_right
Factor XIa and tissue factor activity in patients with coronary artery disease
Anetta Undas
Thrombosis and Haemostasis, 2007
View PDFchevron_right
Combination of Amlexanox and Forskolin Attenuates Pathological Cardiac Hypertrophy by Subduing Maladaptive Inflammatory Response
Seyram Adzraku
2020
View PDFchevron_right
Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis
roby jose
Scientific reports, 2017
View PDFchevron_right
Aspirin Alters the Cardioprotective Effects of the Factor XIII Val34Leu Polymorphism
Anetta Undas
Circulation, 2003
View PDFchevron_right
Angiotensin II binding and extracellular matrix remodelling in a rat model of myocardial infarction
Khalil Bitar
Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000
View PDFchevron_right
AT 1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI
Quang Trinh Nguyen
British Journal of Pharmacology, 2003
View PDFchevron_right
Ivabradine Induces Cardiac Protection against Myocardial Infarction by Preventing Cyclophilin-A Secretion in Pigs under Coronary Ischemia/Reperfusion
Marta Saura
International Journal of Molecular Sciences, 2021
View PDFchevron_right
Early captopril prevents myocardial infarction-induced hypertrophy but not angiogenesis
Regien Schoemaker
European Journal of Pharmacology, 1999
View PDFchevron_right
A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study
Marc Vanderheyden
European Heart Journal, 2001
View PDFchevron_right
Factor VII and extrinsic pathway inhibitor in acute coronary disease
Per Sirnes
British Journal of Haematology, 1989
View PDFchevron_right
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling
Himal Luitel
2012
View PDFchevron_right